PUBLISHER: DataM Intelligence | PRODUCT CODE: 1542865
PUBLISHER: DataM Intelligence | PRODUCT CODE: 1542865
Global Metastatic Bone Pain Market - 2024-2031
Overview
Global Metastatic Bone Pain Market reached US$ 14.4 billion in 2023 and is expected to reach US$ 24 billion by 2031, growing at a CAGR of 6.7% during the forecast period 2024-2031.
Pain is the most common symptom of bone metastases. It tends to be a constant, aching pain that may be worse during activity and can cause sleeping difficulties. Bone pain from cancer tends to be quite different from the pain caused by common conditions such as arthritis or muscular strains.
Market Dynamics: Drivers & Restraints
Rise in the prevalence of cancers
As cancer prevalence increases globally, so does the incidence of bone metastases. Cancers such as breast, prostate, and lung frequently metastasize to bones, leading to a growing need for effective pain management solutions. For instance, according to the American Cancer Society in 2023, the US experienced 1,958,310 new cancer cases and 609,820 deaths, as per the data from central cancer registries and the National Center for Health Statistics, based on population-based cancer occurrence and outcomes.
Complications associated with the drugs
Metastatic bone pain treatments like opioids and radiation therapy have significant side effects, including addiction, tolerance, and health complications. Radiation therapy can cause skin reactions, fatigue, and systemic effects. Surgical interventions, while beneficial in some cases, carry risks of infections, blood loss, and long recovery times.
Market Segment Analysis
The global metastatic bone pain market is segmented based on drug type, route of administration, end-user, and region.
The NSAIDs from the drug type segment accounted for approximately 47.3%. of the metastatic bone pain market share
The NSAIDs from the drug type segment accounted for approximately 47.3%. Non-steroidal anti-inflammatory drugs have been in use for the treatment of pain control for all diseases. They also have an anti-inflammatory effect that makes them an ideal drug for the inflammation caused by certain cancer types during extensive tissue invasion and destruction. A Cochrane review by McNicol and colleagues found that NSAIDs appear to be more effective than placebo for cancer pain.
Market Geographical Share
North America is estimated to hold about 38.4% of the total market share throughout the forecast period
North America is estimated to hold about 38.4% of the total market share throughout the forecast period owing to factors like novel product launches, ongoing clinical trials, FDA approvals, advanced healthcare infrastructure in the region, collaborations and partnerships, and others that help the region to grow during the forecast period.
For instance, in May 2024, the American Society for Radiation Oncology (ASTRO) outlined recommendations on best practices for treating patients with symptomatic bone metastases and strategies to improve their quality of life, according to updated clinical guidelines published by Alcorn et al in Practical Radiation Oncology.
Market Segmentation
By Drug Type
By End User
By Region
Why Purchase the Report?
Table of Contents
1. Methodology and Scope
- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
- 3.1. Snippet by Drug Type
- 3.2. Snippet by Route of Administration
- 3.3. Snippet by End User
- 3.4. Snippet by Region
4. Dynamics
5. Industry Analysis
6. By Drug Type
7. By Route of Administration
8. By End User
9. By Region
10. Competitive Landscape
11. Company Profiles
12. Appendix
